APCDs can Provide Important Insights for Surveilling the Opioid Epidemic,With Caveats

Abstract

State-level all-payer claims databases (APCDs) are a possible new public health surveillance tool, but their reliability is unclear. We compared Colorado’s APCD with other state-level databases for use in monitoring the opioid epidemic (Colorado Hospital Association and Colorado’s Prescription Drug Monitoring Program database for 2010–2017), using descriptive analyses comparing quarterly counts/rates of opioid-involved inpatient and emergency department visits and counts/rates of 30-day opioid fills between databases. Utilization is lower in the Colorado APCD than the other databases for all outcomes but trends are parallel and consistent between databases. State APCDs hold promise for researchers, but they may be better suited to individual-level analyses or comparisons of providers than for surveillance of public health trends related to addiction.

Keywords

All-Payer Claims Database opioid utilization opioid-related harms Colorado Hospital Association Prescription Drug Monitoring Program claims data analysis

Get full access to this article

View all access options for this article.

References

Agency for Healthcare Research and Quality. (2017). Data evaluation of All-Payer Claims Databases: Inventory and prioritization of measures to support the growing effort in transparency using All-Payer Claims Databases. https://www.ahrq.gov/data/apcd/backgroundrpt/data.html

Agency for Healthcare Research and Quality. (2018). All Payer’s Claim Databases. https://www.ahrq.gov/data/apcd/index.html#i

All-Payer Claims Database Council. (2020). Interactive State Report Map. https://www.apcdcouncil.org/state/map

All-Payer Claims Database Council. (2021). Common data layout. https://www.apcdcouncil.org/common-data-layout

Austin

A. M.

Bynum

J. P. W.

Maust

D. T.

Gottlieb

D. J.

Meara

(2018). Long-term implications of a short-term policy: Redacting substance abuse data. Health Affairs, 37(6), 975–979.

Bachhuber

M. A.

Saloner

Cunningham

C. O.

Barry

C. L.

(2014). Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999-2010. JAMA Internal Medicine, 174(10), 1668–1673.

Bartels

Fernandez-Bustamante

McWilliams

S. K.

Hopfer

C. J.

Mikulich-Gilbertson

S. K.

(2018). Long-term opioid use after inpatient surgery—A retrospective cohort study. Drug and Alcohol Dependence, 187, 61–65.

Bradford

A. C.

Bradford

W. D.

(2016). Medical marijuana laws reduce prescription medication use in Medicare Part D. Health Affairs, 35(7), 1230–1236.

Bradford

A. C.

Bradford

W. D.

Abraham

Bagwell Adams

(2018). Association between US state medical cannabis laws and opioid prescribing in the Medicare Part D population. JAMA Internal Medicine, 178(5), 667–672.

10.

Brummett

C. M.

England

Evans-Shields

Kong

A. M.

Lew

C. R.

Henriques

Zimmerman

N. M.

Pawasauskas

Oderda

(2019). Health care burden associated with outpatient opioid use following inpatient or outpatient surgery. Journal of Managed Care & Specialty Pharmacy, 25(9), 973–983.

11.

Burke

L. G.

Zhou

Boyle

K. L.

Orav

E. J.

Bernson

Hood

M. E.

Land

Bharel

Frakt

A. B.

(2020). Trends in opioid use disorder and overdose among opioid-naive individuals receiving an opioid prescription in Massachusetts from 2011 to 2014. Addiction, 115(3), 493–504.

12.

Buttorff

Trujillo

A. J.

Castillo

Vecino-Ortiz

A. I.

Anderson

G. F

. (2017). The impact of practice guidelines on opioid utilization for injured workers. American Journal of Industrial Medicine, 60(12), 1023–1030.

13.

Carman

K. G.

Dworsky

Heins

S. E.

Schwam

Shelton

Whaley

(2021). The history, promise and challenges of State All Payer Claims Databases: Background memo for the State All Payer Claims Database Advisory Committee to the Department of Labor. U.S. Department of Health and Human Services, Office of the Assistant Secretary for Planning and Evaluation.

14.

Center for Improving Value in Health Care. (2020a). CO APCD overview. https://www.civhc.org/get-data/co-apcd-info/

15.

Center for Improving Value in Health Care. (2020b). Plaintalk blog: Why the CO APCD does not have substance use disorder claims. https://www.civhc.org/2019/03/21/plaintalk-blog-why-the-co-apcd-does-not-have-substance-use-disorder-claims/

16.

Center for Improving Value in Health Care. (2021). Colorado State Innovation Model. http://www.civhc.org/change-agent-gallery/colorado-state-innovation-model/

17.

Centers for Disease Control and Prevention. (2014). Drug-poisoning deaths involving opioid analgesics: United States, 1999–2011. https://pubmed.ncbi.nlm.nih.gov/25228059/

18.

Centers for Disease Control and Prevention. (2020). Data resources: Analyzing prescription data and morphine milligram equivalents (MME). https://www.cdc.gov/drugoverdose/resources/data.html

19.

Centers for Medicare & Medicaid Services. (2021). Meaningful measures hub. https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/QualityInitiativesGenInfo/MMF/General-info-Sub-Page#Measurement_Areas

20.

Colorado Hospital Association. (2014). CHA Databank. http://www.cha.com/Member-Services/CHA-DATABANK.aspx

21.

Colorado Revised Statutes Title 18—Criminal Code Article 18—Uniform Controlled Substances Act of 2013. (2017).

22.

Davis

J. M.

Mendelson

Berkes

J. J.

Suleta

Corsi

K. F.

Booth

R. E.

(2016). Public health effects of medical marijuana legalization in Colorado. American Journal of Preventive Medicine, 50(3), 373–379.

23.

Diaz-Perez

M. J.

Hanover

Sites

Rupp

Courtemanche

Levi

. (2019). Producing comparable cost and quality results from All-Payer Claims Databases. The American Journal of Managed Care, 25(5), e138–e144.

24.

Dilonardo

Chalk

Mark

T. L.

Coffey

R. M., &

CSAT/CMHS Spending Estimates Team. (2000). Recent trends in the financing of substance abuse treatment: Implications for the future. Health Services Research, 35(5, Pt 3), 60–71.

25.

Frakt

A. B.

Bagley

(2015). Protection or harm? Suppressing substance-use data. The New England Journal of Medicine, 372(20), 1879–1881.

26.

Guy

Haegerich

T. M.

Evans

M. E.

Losby

J. L.

Young

Jones

C. M.

(2019). Vital signs: Pharmacy-based naloxone dispensing—United States, 2012-2018. Morbidity and Mortality Weekly Report, 68(31), 679–686.

27.

Heins

S. E.

Feldman

D. R.

Bodycombe

Wegener

S. T.

Castillo

R. C.

(2016). Early opioid prescription and risk of long-term opioid use among US workers with back and shoulder injuries: A retrospective cohort study. Injury Prevention, 22(3), 211–215.

28.

Heins

S. E.

Sorbero

M. J.

Jones

C. M.

Dick

A. W.

Stein

B. D.

(2018). High-risk prescribing to Medicaid enrollees receiving opioid analgesics: Individual- and county-level factors. Substance Use & Misuse, 53(10), 1591–1601.

29.

IQVIA. (2018). Medicine use and spending in the U.S.: A review of 2017 and Outlook to 2022. IQVIA Institute for Human Data Science.

30.

Kirson

N. Y.

White

A. G.

Birnbaum

H. G.

Schiller

Waldman

Peterson

Ben-Joseph

R. H.

Berner

Summers

K. H.

(2012). Direct and indirect costs of patients treated with extended-release oxymorphone HCl or controlled-release oxycodone HCl. Journal of Medical Economics, 15(1), 87–95.

31.

LeBaron

V. T.

Camacho

Balkrishnan

Yao

N. A.

Gilson

A. M.

(2019). Opioid epidemic or pain crisis? Using the Virginia All Payer Claims Database to describe opioid medication prescribing patterns and potential harms for patients with cancer. Journal of Oncology Practice, 15(12), e997–e1009.

32.

Liu

Scholl

Hoots

Seth

(2020). Nonfatal drug and polydrug overdoses treated in emergency departments—29 states, 2018-2019. Morbidity and Mortality Weekly Report, 69(34), 1149–1155.

33.

Livingston

M. D.

Barnett

T. E.

Delcher

Wagenaar

A. C.

(2017). Recreational cannabis legalization and opioid-related deaths in Colorado, 2000-2015. American Journal of Public Health, 107(11), 1827–1829.

34.

Malon

Shah

Koh

W. Y.

Cattabriga

Cao

(2018). Characterizing the demographics of chronic pain patients in the state of Maine using the Maine all payer claims database. BMC Public Health, 18(1), Article 810.

35.

Mattson

C. L.

Tanz

L. J.

Quinn

Kariisa

Patel

Davis

N. L

. (2021). Trends and geographic patterns in drug and synthetic opioid overdose deaths — United States, 2013–2019. MMWR Morbidity and Mortality Weekly Report, 70(6), 202–207. http://dx.doi.org/10.15585/mmwr.mm7006a4

36.

McCarthy

(2020, December 10). State All-Payer Claims Databases: Tools for improving health care value, part 2 [Report]. The Commonwealth Fund.

37.

National Institute on Drug Abuse. (2020). Colorado: Opioid-involved deaths and related harms. https://www.drugabuse.gov/drug-topics/opioids/opioid-summaries-by-state/colorado-opioid-involved-deaths-related-harms

38.

Panhans

(2019). Adverse selection in ACA exchange markets: Evidence from Colorado. American Economic Journal: Applied Economics, 11(2), 1–36.

39.

Peters

Sachs

Porter

Love

Costello

(2014). The value of All-Payer Claims Databases to states. North Carolina Medical Journal, 75(3), 211–213.

40.

Rocco

Kelly

A. S.

Beland

Kinane

(2017). The new politics of US health care prices: Institutional reconfiguration and the emergence of All-Payer Claims Databases. Journal of Health Politics, Policy and Law, 42(1), 5–52.

41.

Rudd

R. A.

Seth

David

Scholl

(2016). Increases in drug and opioid-involved overdose deaths—United States, 2010-2015. Morbidity and Mortality Weekly Report, 65(50–51), 1445–1452.

42.

Saloner

Daubresse

Caleb Alexander

(2017). Patterns of buprenorphine-naloxone treatment for opioid use disorder in a multistate population. Medical Care, 55(7), 669–676.

43.

Schieber

L. Z.

Guy

Seth

Young

Mattson

C. L.

Mikosz

C. A.

Schieber

R. A.

(2019). Trends and patterns of geographic variation in opioid prescribing practices by state, United States, 2006-2017. JAMA Network Open, 2(3), Article e190665.

44.

Scholl

Seth

Kariisa

Wilson

Baldwin

(2018). Drug and opioid-involved overdose deaths—United States, 2013-2017. Morbidity and Mortality Weekly Report, 67(5152), 1419–1427.

45.

Shi

Liang

Bao

Wallace

M. S.

Grant

(2019). Recreational marijuana legalization and prescription opioids received by Medicaid enrollees. Drug and Alcohol Dependence, 194, 13–19.

46.

Smart

Kase

C. A. M.

Stein

(2018). Data sources and data-linking strategies to support research to address the opioid crisis. U.S. Department of Health and Human Services Assistant Secretary for Planning and Evaluation, Office of Health Policy.

47.

Substance Abuse and Mental Health Services Administration. (2017). Federal Register: 42 CFR part 2: Confidentiality of substance use disorder patient records: Final rule—Rules and regulations (pp. 6052–6127). Department of Health and Human Services.

48.

Tenney

McKenzie

L. M.

Matus

Mueller

Newman

L. S.

(2019). Effect of an opioid management program for Colorado workers’ compensation providers on adherence to treatment guidelines for chronic pain. American Journal of Industrial Medicine, 62(1), 21–29.

49.

Wen

Hockenberry

J. M.

(2018). Association of medical and adult-use marijuana laws with opioid prescribing for Medicaid enrollees. JAMA Internal Medicine, 178(5), 673–679.